November 21, 2024 05:30 PM ESTUpdated 06:13 PM
R&D
Cell/Gene Tx

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Jared Whitlock

Features Editor

A fe­male Rett syn­drome pa­tient died Wednes­day af­ter re­ceiv­ing Neu­ro­gene’s gene ther­a­py in a clin­i­cal tri­al, the com­pa­ny dis­closed in a new

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times